Who Paid My Doc
Matt Morgan
Surgery Pella, IA Doctor of Osteopathy
NPI 1447275722 CMS profile 292104
405 Monroe St, Pella, IA 50219
General payments
$22,514
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Matt Morgan of Pella, IA is reported in the CMS Open Payments database as having received $22,514 across 96 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,459 | 14 | |
| 2024 | General | $6,132 | 15 | |
| 2023 | General | $563 | 6 | |
| 2022 | General | $46 | 3 | |
| 2021 | General | $152 | 6 | |
| 2020 | General | $318 | 8 | |
| 2019 | General | $13,844 | 44 |
Beside peers
- Matt Morgan
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Matt Morgan were reported at $1,459. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Matt Morgan | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,844 | $253 | $82–$1,521 | $163 |
| 2020 | $318 | $131 | $40–$706 | $114 |
| 2021 | $152 | $168 | $50–$904 | $132 |
| 2022 | $46 | $224 | $76–$1,218 | $149 |
| 2023 | $563 | $253 | $82–$1,255 | $160 |
| 2024 | $6,132 | $279 | $90–$1,381 | $164 |
| 2025 | $1,459 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
253
Drug cost
$7,111
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | Brand | 179 | $3,678 | |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | Brand | 12 | $1,961 | |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | Brand | 15 | $981 | |
| Gavilyte-N Sodium Chloride/Nahco3/Kcl/Peg | Brand | 35 | $442 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 12 | $50 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$6,724
Medicare patients
14
Services billed
23
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
96 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in Iowa
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.